Tatyana Moiseenko
Research Subjects
Tatyana Moiseenko has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Elena Mikhaylovna Frantsiyants
National Medical Research Center of Oncology, Ministry of Health of Russia
14 shared publications - Anna Petrovna Men'SHenina
National Medical Research Center of Oncology, Ministry of Health of Russia
11 shared publications - Ekaterina V. Verenikina
National Medical Research Centre for Oncology
8 shared publications - Irina Viktorovna Kaplieva
Rostov Research Institute of Oncology
5 shared publications - Valeriya Akhtyamovna Bandovkina
National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Ekaterina Igorevna Surikova
National Medical Research Centre for Oncology Rostov-on-Don, Russian Federation
4 shared publications
Latest Publications
- Open Access
- 21 September 2025
- Published by Publishing House ABV Press in MD-Onco
- Vol. 5 (3) , 29-37
Effects of sonodynamic component of neoadjuvant chemotherapy on treatment outcomes of cervical cancer patients
Aim. The present study aims to investigate the efficacy of a modified combination neoadjuvant polychemotherapy (NACT) with a sonodynamic component in patients diagnosed with stage IIA2 locally advanced cervical cancer.Materials and methods. The study encompassed data from 82 patients diagnosed with locally advanced cervical cancer, classified as stage IIA2 (T2a2N0M0). All patients underwent NACT courses according to the cisplatin and bleomycetin regimen. Patients in the control group (n = 32) underwent intravenous NACT, while patients in the main group (n = 50) underwent intravenous NACT in conjunction with contact sonodynamic chemotherapy comprising 5-fluorouracil. The number of NACT courses ranged from two to three, contingent upon the immediate treatment outcomes. Following the attainment of complete or partial regression of the tumor, an extended nerve-sparing extirpation of the uterus, including the appendages, was performed. In instances where the initial treatment did not yield the desired outcome, that is, stabilization of the process, the subsequent treatment plan involved the administration of chemoradiation therapy.Results. The study revealed that patients in the experimental group demonstrated a substantially higher degree of resectability following two cycles of NACT with a sonodynamic component when compared to the control group. The observed values were 94 and 56.2 %, respectively (p 0.05). A greater proportion of patients in the control group required the third course of NACT, with 43.75 % of patients requiring this intervention, compared to 6 % of patients in the main group (p 0.05). The prevalence of drug-induced pathomorphosis grades III–IV in the main group was documented in 64.3 % of cases, while in the control group drug-induced pathomorphosis grades I–II were predominant (60 %). The overall 5-year survival rate of patients in the primary cohort was notably higher than that of the control group. The study revealed that 82.1 % of the subjects in the first group exhibited a positive response, in contrast to 63.6 % of the subjects in the second group (p 0.05). The five-year relapse-free survival rate in the primary cohort was 78.8 ± 9.5 %, while in the control group, it was 58.8 ± 6.2 % (p 0.05). Conclusion. The application of accelerated regression of cancer tumors under the influence of combined NACT has been demonstrated to result in a reduction in the number of NACT courses and an increase in the number of optimal radical surgeries. The efficacy of the method was substantiated by the findings of morphological and immunohistochemical studies, as evidenced by the indicators of 5-year overall and relapsefree survival for this patient population.
- 21 September 2025
- Published by Publishing House ABV Press in MD-Onco
- Vol. 5 (3) , 29-37
Open AccessEffects of sonodynamic component of neoadjuvant chemotherapy on treatment outcomes of cervical cancer patients
Aim. The present study aims to investigate the efficacy of a modified combination neoadjuvant polychemotherapy (NACT) with a sonodynamic component in patients diagnosed with stage IIA2 locally advanced cervical cancer.Materials and methods. The study encompassed data from 82 patients diagnosed with locally advanced cervical cancer, classified as stage IIA2 (T2a2N0M0). All patients underwent NACT courses according to the cisplatin and bleomycetin regimen. Patients in the control group (n = 32) underwent intravenous NACT, while patients in the main group (n = 50) underwent intravenous NACT in conjunction with contact sonodynamic chemotherapy comprising 5-fluorouracil. The number of NACT courses ranged from two to three, contingent upon the immediate treatment outcomes. Following the attainment of complete or partial regression of the tumor, an extended nerve-sparing extirpation of the uterus, including the appendages, was performed. In instances where the initial treatment did not yield the desired outcome, that is, stabilization of the process, the subsequent treatment plan involved the administration of chemoradiation therapy.Results. The study revealed that patients in the experimental group demonstrated a substantially higher degree of resectability following two cycles of NACT with a sonodynamic component when compared to the control group. The observed values were 94 and 56.2 %, respectively (p 0.05). A greater proportion of patients in the control group required the third course of NACT, with 43.75 % of patients requiring this intervention, compared to 6 % of patients in the main group (p 0.05). The prevalence of drug-induced pathomorphosis grades III–IV in the main group was documented in 64.3 % of cases, while in the control group drug-induced pathomorphosis grades I–II were predominant (60 %). The overall 5-year survival rate of patients in the primary cohort was notably higher than that of the control group. The study revealed that 82.1 % of the subjects in the first group exhibited a positive response, in contrast to 63.6 % of the subjects in the second group (p 0.05). The five-year relapse-free survival rate in the primary cohort was 78.8 ± 9.5 %, while in the control group, it was 58.8 ± 6.2 % (p 0.05). Conclusion. The application of accelerated regression of cancer tumors under the influence of combined NACT has been demonstrated to result in a reduction in the number of NACT courses and an increase in the number of optimal radical surgeries. The efficacy of the method was substantiated by the findings of morphological and immunohistochemical studies, as evidenced by the indicators of 5-year overall and relapsefree survival for this patient population.
- Open Access
- 20 February 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (1) , 50-59
Free radical oxidation and antioxidant defense in uterine myoma and endometrioid adenocarcinoma depending on its degree of differentiation
Purpose of the study. To evaluate the features of free radical oxidation (FRO) and the principal enzymatic and non-enzymatic links of antioxidant defense in proliferating tissues of benign myoma and malignant endometrioid adenocarcinoma (EA) with varying degrees of differentiation.Patients and methods. Patients who received surgical treatment for EA (n = 42) and uterine myoma (n = 14) were examined. Patients with stage Ia (n = 26) and stage Ib (n = 16) of disease were selected. 16 patients had highly differentiated (G1) EA, 12 had moderately differentiated (G2) EA, and 14 had low-differentiated (G3) EA. The activity of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione transferase (GST), reduced glutathione (GSH), vitamins A and E, lipid peroxidation products diene conjugates (DC) and malondialdehyde (MDA) were determined colorimetrically in the tissues of EA, myoma and intact uterus.Results. Compared with the level in intact tissue, SOD decreased by 3.2 times and GST increased by 2.7 times in myoma (p < 0.01). Similar changes were noted for EA G1 – on average by 5.3 times (p < 0.01) and also DC increased by 2.2 times (p < 0.05). In EA G2 tissue, SOD and GPx activities were lower than in the intact tissue, by 5.7 and 4.5 times, respectively (p < 0.05), and lower GST, GPx and GSH than in the EA G1, by 4.9, 8.9 and 1.6 times, respectively (p < 0.05 – p < 0.01). In EA G3 tissue, there was an increase in GSH, GPx and GST from 1.5 to 7.1 times (p < 0.05 – p < 0.01) and lipid peroxidation products by an average of 2.5 times (p < 0.05), as well as a decrease in vitamins A and E by 2.9 and 4.6 times, respectively (p < 0.05) compared with the intact tissue. The tissue of the EA G2 had a minimal level of activity of the GSH-dependent system.Conclusion. The results reflect the differences in the mechanisms of proliferation regulation by FRO in myomas and in the EA tissue with changes in its differentiation. Knowledge of the characteristics of individual links in the regulation of FRO can play a certain role in the use of antioxidant therapy for benign or malignant tumors of the uterus.
- 20 February 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (1) , 50-59
Open AccessFree radical oxidation and antioxidant defense in uterine myoma and endometrioid adenocarcinoma depending on its degree of differentiation
Purpose of the study. To evaluate the features of free radical oxidation (FRO) and the principal enzymatic and non-enzymatic links of antioxidant defense in proliferating tissues of benign myoma and malignant endometrioid adenocarcinoma (EA) with varying degrees of differentiation.Patients and methods. Patients who received surgical treatment for EA (n = 42) and uterine myoma (n = 14) were examined. Patients with stage Ia (n = 26) and stage Ib (n = 16) of disease were selected. 16 patients had highly differentiated (G1) EA, 12 had moderately differentiated (G2) EA, and 14 had low-differentiated (G3) EA. The activity of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione transferase (GST), reduced glutathione (GSH), vitamins A and E, lipid peroxidation products diene conjugates (DC) and malondialdehyde (MDA) were determined colorimetrically in the tissues of EA, myoma and intact uterus.Results. Compared with the level in intact tissue, SOD decreased by 3.2 times and GST increased by 2.7 times in myoma (p < 0.01). Similar changes were noted for EA G1 – on average by 5.3 times (p < 0.01) and also DC increased by 2.2 times (p < 0.05). In EA G2 tissue, SOD and GPx activities were lower than in the intact tissue, by 5.7 and 4.5 times, respectively (p < 0.05), and lower GST, GPx and GSH than in the EA G1, by 4.9, 8.9 and 1.6 times, respectively (p < 0.05 – p < 0.01). In EA G3 tissue, there was an increase in GSH, GPx and GST from 1.5 to 7.1 times (p < 0.05 – p < 0.01) and lipid peroxidation products by an average of 2.5 times (p < 0.05), as well as a decrease in vitamins A and E by 2.9 and 4.6 times, respectively (p < 0.05) compared with the intact tissue. The tissue of the EA G2 had a minimal level of activity of the GSH-dependent system.Conclusion. The results reflect the differences in the mechanisms of proliferation regulation by FRO in myomas and in the EA tissue with changes in its differentiation. Knowledge of the characteristics of individual links in the regulation of FRO can play a certain role in the use of antioxidant therapy for benign or malignant tumors of the uterus.
- Open Access
- 4 December 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (4) , 58-72
Uterine sarcoma: the possibility of modeling a rare tumor and providing its morphological description
Purpose of the study. To create a model of uterine sarcoma in female white mongrel rats and provide description of its morphological features. Materials and methods. In the in vivo experiment, white mongrel female laboratory rats (n = 20) weighing 250 ± 25 g were used, and the M1 strain of rat sarcoma was used as an experimental tumor model. The studied groups of animals: Group 1 (n = 10) – administration of 0.5 ml of tumor suspension containing 2.5–3.5 × 106 cells using an intravenous catheter with an injection port 22G, 0.9 × 25 mm; group 2 (n = 10) – donors of tumor material with subcutaneous M1 grafting according to the standard method. Xylazine‑ zolethyl anesthesia was used during surgical interventions. The duration of the experiment was 21 days. After killing the animals, median longitudinal histological sections were made from the tumor node, 5–7 microns thick, stained with hematoxylin‑ eosin. Results. Unlike subcutaneous grafting of sarcoma M1, the tumor growing in the uterine horn was characterized by the presence in the abdominal cavity of many nodules and tumor dropouts on the mesentery, i. e. lymph nodes. According to the cellular composition, tumors formed from a suspension of M1 sarcoma cells injected into the right horn of the uterus were characterized by a polymorphocellular type of structure against the background of pronounced neoangiogenesis. Necrosis and hemorrhages were noted in certain sections of the preparations with a polyp‑like tumor form, which corresponds to destructive signs of rapid growth and development of uterine sarcoma. Conclusion. The possibility of modeling a relatively rare tumor by introducing a suspension of M1 sarcoma cells into the right uterine horn of female rats has been established. The nature of multinodular tumor growth with pronounced polymorphism of the cellular composition, areas of necrotization and hemorrhage demonstrates the adequacy of the uterine sarcoma model for the implementation of research tasks in clinical oncology.
- 4 December 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (4) , 58-72
Open AccessUterine sarcoma: the possibility of modeling a rare tumor and providing its morphological description
Purpose of the study. To create a model of uterine sarcoma in female white mongrel rats and provide description of its morphological features. Materials and methods. In the in vivo experiment, white mongrel female laboratory rats (n = 20) weighing 250 ± 25 g were used, and the M1 strain of rat sarcoma was used as an experimental tumor model. The studied groups of animals: Group 1 (n = 10) – administration of 0.5 ml of tumor suspension containing 2.5–3.5 × 106 cells using an intravenous catheter with an injection port 22G, 0.9 × 25 mm; group 2 (n = 10) – donors of tumor material with subcutaneous M1 grafting according to the standard method. Xylazine‑ zolethyl anesthesia was used during surgical interventions. The duration of the experiment was 21 days. After killing the animals, median longitudinal histological sections were made from the tumor node, 5–7 microns thick, stained with hematoxylin‑ eosin. Results. Unlike subcutaneous grafting of sarcoma M1, the tumor growing in the uterine horn was characterized by the presence in the abdominal cavity of many nodules and tumor dropouts on the mesentery, i. e. lymph nodes. According to the cellular composition, tumors formed from a suspension of M1 sarcoma cells injected into the right horn of the uterus were characterized by a polymorphocellular type of structure against the background of pronounced neoangiogenesis. Necrosis and hemorrhages were noted in certain sections of the preparations with a polyp‑like tumor form, which corresponds to destructive signs of rapid growth and development of uterine sarcoma. Conclusion. The possibility of modeling a relatively rare tumor by introducing a suspension of M1 sarcoma cells into the right uterine horn of female rats has been established. The nature of multinodular tumor growth with pronounced polymorphism of the cellular composition, areas of necrotization and hemorrhage demonstrates the adequacy of the uterine sarcoma model for the implementation of research tasks in clinical oncology.
- Open Access
- 7 November 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (4) , 23-35
Tumor and peritumoral tissue hormonal background features in patients with rare types of endometrial cancer
Serous endometrial intraepithelial carcinoma (SEIC) and clear cell carcinoma of the endometrium (CCEC) belong to pathogenetic type II without evidence of hyperestrogenism, are often detected late in the course of the disease, and are characterized by an aggressive course. Currently, there is increasing interest in the role of local content and metabolism of steroid hormones in organs and tissues in various pathologies, including the development of malignant tumors. Purpose of the study. To determine the local level of sex hormones in patients with SEIC and CCEC. Patients and methods. The study included 21 patients with SEIC and 20 patients with CCEC. The control group consisted of 20 patients who had undergone surgical treatment for uterine myoma. All patients were treated at the National Medical Research Center for Oncology, Rostov‑on‑ Don, the Russian Federation Ministry of Health. The local levels of estrogens and androgens were determined in the tumor tissue, the perifocal zone, endometrial tissue unaffected by the tumor process, and the fallopian tube tissue in patients with SEIC and CCEC. In the control group, the local level of sex hormones was determined in intact 10 % homogenic endometrial tissue. Results. The data were analyzed, and the results demonstrated that the tumors and peritumoral tissues exhibited a depletion of estradiol (E2), a saturation of testosterone, and an extreme saturation of estriol (E3). The consequence of this imbalance was the predominance of fetal placental estrogen (E3), which was detected not only in the tumor tissue but also in distant parts of the endometrium and uterine tubes. In these regions, the concentration of E3 exceeded that of intact endometrium by a factor of more than five. A comparison of estrogen receptor (ER) levels revealed elevated levels in samples of the tumor, its perifocal zone, distant endometrium, and fallopian tubes. This finding indicated a predominance of ERα over ERβ. Conclusion. The local hormonal background of rare forms of non‑endometrioid endometrial carcinomas exhibits distinctive characteristics, including the replacement of the influence of classical estrogen (E2) by fetal, placental E3. Additionally, there is a notable prevalence of the REα type over REβ, along with hyperandrogenization of tissues, which culminates in the formation of a unique low‑differentiated tumor with pronounced biological aggressiveness.
- 7 November 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (4) , 23-35
Open AccessTumor and peritumoral tissue hormonal background features in patients with rare types of endometrial cancer
Serous endometrial intraepithelial carcinoma (SEIC) and clear cell carcinoma of the endometrium (CCEC) belong to pathogenetic type II without evidence of hyperestrogenism, are often detected late in the course of the disease, and are characterized by an aggressive course. Currently, there is increasing interest in the role of local content and metabolism of steroid hormones in organs and tissues in various pathologies, including the development of malignant tumors. Purpose of the study. To determine the local level of sex hormones in patients with SEIC and CCEC. Patients and methods. The study included 21 patients with SEIC and 20 patients with CCEC. The control group consisted of 20 patients who had undergone surgical treatment for uterine myoma. All patients were treated at the National Medical Research Center for Oncology, Rostov‑on‑ Don, the Russian Federation Ministry of Health. The local levels of estrogens and androgens were determined in the tumor tissue, the perifocal zone, endometrial tissue unaffected by the tumor process, and the fallopian tube tissue in patients with SEIC and CCEC. In the control group, the local level of sex hormones was determined in intact 10 % homogenic endometrial tissue. Results. The data were analyzed, and the results demonstrated that the tumors and peritumoral tissues exhibited a depletion of estradiol (E2), a saturation of testosterone, and an extreme saturation of estriol (E3). The consequence of this imbalance was the predominance of fetal placental estrogen (E3), which was detected not only in the tumor tissue but also in distant parts of the endometrium and uterine tubes. In these regions, the concentration of E3 exceeded that of intact endometrium by a factor of more than five. A comparison of estrogen receptor (ER) levels revealed elevated levels in samples of the tumor, its perifocal zone, distant endometrium, and fallopian tubes. This finding indicated a predominance of ERα over ERβ. Conclusion. The local hormonal background of rare forms of non‑endometrioid endometrial carcinomas exhibits distinctive characteristics, including the replacement of the influence of classical estrogen (E2) by fetal, placental E3. Additionally, there is a notable prevalence of the REα type over REβ, along with hyperandrogenization of tissues, which culminates in the formation of a unique low‑differentiated tumor with pronounced biological aggressiveness.
- 30 March 2024
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 85 (1) , 97-101
The role of androgens in the pathogenesis of endometrial cancer
Over the past decades, endometrial cancer has become the most common gynecological cancer worldwide. Its increasing incidence cannot be attributed only to the increasing age of women in socially secure countries. The leading risk factor for the endometrial cancer development is obesity, and its epidemic is gradually covering the female population of North Africa, Europe and Asia. Endometrial cancer is pathogenetically associated with hyperestrogenism, and this was the basis for the dualistic theory of clinical and pathological variants proposed by Ya.V. Bohman. The foundations of this theory about the hormonal dependence of endometrial cancer are now being actively supplemented by molecular genetic parameters of the TCGA classification. Recent studies show steroid dependence of endometrial cancer both on estrogens and, to a large extent, on androgens which are directly involved in the complex processes of transformation into estrogens. Published research data, rather contradictory and ambiguous, confirm the antiproliferative role of androgens in the pathogenesis of endometrial cancer. This review analyzes papers on the role of androgens in pathogenesis and their potential clinical antitumor application. Keywords: endometrial cancer, androgens, androgen receptor, classification of endometrial cancer.
- 30 March 2024
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 85 (1) , 97-101
The role of androgens in the pathogenesis of endometrial cancer
Over the past decades, endometrial cancer has become the most common gynecological cancer worldwide. Its increasing incidence cannot be attributed only to the increasing age of women in socially secure countries. The leading risk factor for the endometrial cancer development is obesity, and its epidemic is gradually covering the female population of North Africa, Europe and Asia. Endometrial cancer is pathogenetically associated with hyperestrogenism, and this was the basis for the dualistic theory of clinical and pathological variants proposed by Ya.V. Bohman. The foundations of this theory about the hormonal dependence of endometrial cancer are now being actively supplemented by molecular genetic parameters of the TCGA classification. Recent studies show steroid dependence of endometrial cancer both on estrogens and, to a large extent, on androgens which are directly involved in the complex processes of transformation into estrogens. Published research data, rather contradictory and ambiguous, confirm the antiproliferative role of androgens in the pathogenesis of endometrial cancer. This review analyzes papers on the role of androgens in pathogenesis and their potential clinical antitumor application. Keywords: endometrial cancer, androgens, androgen receptor, classification of endometrial cancer.
- 17 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 35-41
Pathogenetic characteristics of endometrioid adenocarcinoma of uterus at present stage
Endometrial cancer (EC) is one of the most common cancers with a constantly and steadily growing incidence worldwide. The main reason for EC development, in addition to the female population aging, involves the obesity epidemic and associated hyperinsulinemia. Screening for EC has not been developed. However, endometrial carcinoma (ECa) demonstrates a specific symptomatology and clinical picture, and diagnostic methods are available, sensitive and defined by a certain range of comorbid diseases. These factors allow early ECa diagnosis in 80 %. The methods of treatment are standardized, depending on the stage of RTM and the morphological structure of EC, the age of the patient and allow to achieve 72–76 % of the overall 5-year survival rate. The methods of treatment are standardized, depending on the EC stage, the morphological structure of ECa, and the patient’s age, and allow achieving the 5-year overall survival of 72–76 %. The disease promised a favorable outcome and seemed to be controlled. However, at the end of the last century, researchers started to report the clinical and morphological heterogeneity of ECa, which allowed Ya. V. Bohman to propose a dichotomous division of EC into clinical and pathological variants. Such a division was accepted all over the world and required re-evaluation of the prognostic value of various endometrial adenocarcinoma histotypes depending on the phenotype and hormonogenesis of ECa. Initially, adenosquamous cancer (or endometrioid adenocarcinoma with squamous metaplasia, in the modern classification) was also classified as estrogen-dependent endometrioid adenocarcinoma, and squamous cell endometrial cancer was classified as an unfavorable type with a poor prognosis and without hormonal influence. Interest in the squamous cell component in dimorphic endometrial adenocarcinoma has repeatedly arisen over the past decades due to its unpredictable clinical course. The newest TCGA molecular classification of EC did not clarify the issues, but gave rise to new ones related to the etiology and carcinogenesis of this ECa histotype and its clinical interpretation.
- 17 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 35-41
Pathogenetic characteristics of endometrioid adenocarcinoma of uterus at present stage
Endometrial cancer (EC) is one of the most common cancers with a constantly and steadily growing incidence worldwide. The main reason for EC development, in addition to the female population aging, involves the obesity epidemic and associated hyperinsulinemia. Screening for EC has not been developed. However, endometrial carcinoma (ECa) demonstrates a specific symptomatology and clinical picture, and diagnostic methods are available, sensitive and defined by a certain range of comorbid diseases. These factors allow early ECa diagnosis in 80 %. The methods of treatment are standardized, depending on the stage of RTM and the morphological structure of EC, the age of the patient and allow to achieve 72–76 % of the overall 5-year survival rate. The methods of treatment are standardized, depending on the EC stage, the morphological structure of ECa, and the patient’s age, and allow achieving the 5-year overall survival of 72–76 %. The disease promised a favorable outcome and seemed to be controlled. However, at the end of the last century, researchers started to report the clinical and morphological heterogeneity of ECa, which allowed Ya. V. Bohman to propose a dichotomous division of EC into clinical and pathological variants. Such a division was accepted all over the world and required re-evaluation of the prognostic value of various endometrial adenocarcinoma histotypes depending on the phenotype and hormonogenesis of ECa. Initially, adenosquamous cancer (or endometrioid adenocarcinoma with squamous metaplasia, in the modern classification) was also classified as estrogen-dependent endometrioid adenocarcinoma, and squamous cell endometrial cancer was classified as an unfavorable type with a poor prognosis and without hormonal influence. Interest in the squamous cell component in dimorphic endometrial adenocarcinoma has repeatedly arisen over the past decades due to its unpredictable clinical course. The newest TCGA molecular classification of EC did not clarify the issues, but gave rise to new ones related to the etiology and carcinogenesis of this ECa histotype and its clinical interpretation.
- Open Access
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 36-49
Effect of dendritic cell vaccine on blood redox status in patients with cervical cancer
Purpose of the study. The purpose of the study was to evaluate the dynamics of parameters of malondialdehyde (MDA), reduced glutathione and antioxidant enzyme activity in patients with advanced cervical cancer (CC) receiving anticancer treatment with dendritic cell vaccine (DCV).Patients and methods. Levels of malondialdehyde (MDA), reduced glutathione and antioxidant enzyme activity were studied in 27 patients aged 27–65 years with advanced primary and recurrent CC receiving chemotherapy (CT) with DCV or DCV as monotherapy at a dose of 10 million cells intradermally once a week. The same indices were studied in 20 healthy women from the comparison group.Results. The majority of patients showed the initial increase of MDA: in blood plasma by an average of 66.7 %, in red blood cells – statistically insignificant. After CT, MDA levels were elevated respectively in primary and recurrent patients in erythrocytes by 85.6 % and 96.4 % compared to donors, and by 53.9 % and 33.7 % compared to the initial values; the levels in plasma were elevated by 79.8 % and 57.1 % compared to donors. After 5–7 DCVs in combination with CT, MDA levels in erythrocytes and in blood plasma were similar to the donor values. MDA in erythrocytes of patients receiving DCV without CT decreased by 36 % compared to initial values. Oxidase activity of ceruloplasmin, initially increased by 34.2–57.1 %, normalized after DCV. Superoxide dismutase activity decreased by 16.7–27.3 % after 4–6 DCVs and normalized after 7 DCVs. Catalase activity, initially reduced by more than 40 %, remained 20–38 % lower than the norm at all stages of DCV. In this setting, hydrogen peroxide was probably inactivated by glutathione peroxidase whose activity was increased at all stages of treatment and decreased only when MDA was normalized after 7 DCVs.Conclusion. Administration of 5–7 DCVs in combination with CT or as monotherapy to patients with advanced CC normalizes parameters of free radical oxidation and antioxidant system of the blood.
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 36-49
Open AccessEffect of dendritic cell vaccine on blood redox status in patients with cervical cancer
Purpose of the study. The purpose of the study was to evaluate the dynamics of parameters of malondialdehyde (MDA), reduced glutathione and antioxidant enzyme activity in patients with advanced cervical cancer (CC) receiving anticancer treatment with dendritic cell vaccine (DCV).Patients and methods. Levels of malondialdehyde (MDA), reduced glutathione and antioxidant enzyme activity were studied in 27 patients aged 27–65 years with advanced primary and recurrent CC receiving chemotherapy (CT) with DCV or DCV as monotherapy at a dose of 10 million cells intradermally once a week. The same indices were studied in 20 healthy women from the comparison group.Results. The majority of patients showed the initial increase of MDA: in blood plasma by an average of 66.7 %, in red blood cells – statistically insignificant. After CT, MDA levels were elevated respectively in primary and recurrent patients in erythrocytes by 85.6 % and 96.4 % compared to donors, and by 53.9 % and 33.7 % compared to the initial values; the levels in plasma were elevated by 79.8 % and 57.1 % compared to donors. After 5–7 DCVs in combination with CT, MDA levels in erythrocytes and in blood plasma were similar to the donor values. MDA in erythrocytes of patients receiving DCV without CT decreased by 36 % compared to initial values. Oxidase activity of ceruloplasmin, initially increased by 34.2–57.1 %, normalized after DCV. Superoxide dismutase activity decreased by 16.7–27.3 % after 4–6 DCVs and normalized after 7 DCVs. Catalase activity, initially reduced by more than 40 %, remained 20–38 % lower than the norm at all stages of DCV. In this setting, hydrogen peroxide was probably inactivated by glutathione peroxidase whose activity was increased at all stages of treatment and decreased only when MDA was normalized after 7 DCVs.Conclusion. Administration of 5–7 DCVs in combination with CT or as monotherapy to patients with advanced CC normalizes parameters of free radical oxidation and antioxidant system of the blood.
- Open Access
- 4 May 2022
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 9 (2) , 34-49
Endotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer
Purpose of the study. Assessment of albumin and endogenous intoxication levels in patients with locally advanced cervical cancer receiving immunotherapy with dendritic cell vaccine.Materials and methods. The study included 27 patients with advanced cervical cancer (CC) divided into 3 groups: 1) patients receiving dendritic cell vaccine (DCV) during primary chemoradiation treatment; 2) patients with the disease progression receiving DCV during second‑line chemotherapy; 3) patients with advanced disease with contraindications for chemo‑radiation treatment receiving DCV only. The comparison group included 20 healthy women. All groups were tested for levels of medium‑weight molecules (MWM254 and MWM280), total and effective concentrations of albumin (TCA and ECA), toxicity index (TI) characterizing the sorption capacity of albumin, and the coefficient of intoxication (CI) reflecting the balance between the accumulation and binding of toxic ligands.Results. Initial elevation of MWM was observed in all patients. Levels of MWM254 were the highest in patients with progression. TI in patients with primary and progressive CC was increased before the treatment by 1.7 and 2.2 times, and after CT (without DCV) – by 2.6 and 3.8 times. In group 3, TI was increased by 4 times, and CI by 2.5 times, being 81 % higher than in group 1. In primary patients, TI after 6 and 7 DCVs was similar to the normal values, and CI was increased during the treatment because of the accumulation of MWM254 due to disintegration of tumor masses in these patients, and then it was normalized after 7 DCVs. CI in patients of groups 2 and 3 decreased after each DCV session. 4 and more DCVs restored the functional activity of albumin and normalized the MWM content.Conclusion. Administration of DCV (at least 7–8 sessions) in CC patients receiving anticancer treatment or as monotherapy decreases endotoxicosis and restores detoxification capacity of albumin.
- 4 May 2022
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 9 (2) , 34-49
Open AccessEndotoxemia in immunotherapy with dendritic cell vaccine in patients with advanced cervical cancer
Purpose of the study. Assessment of albumin and endogenous intoxication levels in patients with locally advanced cervical cancer receiving immunotherapy with dendritic cell vaccine.Materials and methods. The study included 27 patients with advanced cervical cancer (CC) divided into 3 groups: 1) patients receiving dendritic cell vaccine (DCV) during primary chemoradiation treatment; 2) patients with the disease progression receiving DCV during second‑line chemotherapy; 3) patients with advanced disease with contraindications for chemo‑radiation treatment receiving DCV only. The comparison group included 20 healthy women. All groups were tested for levels of medium‑weight molecules (MWM254 and MWM280), total and effective concentrations of albumin (TCA and ECA), toxicity index (TI) characterizing the sorption capacity of albumin, and the coefficient of intoxication (CI) reflecting the balance between the accumulation and binding of toxic ligands.Results. Initial elevation of MWM was observed in all patients. Levels of MWM254 were the highest in patients with progression. TI in patients with primary and progressive CC was increased before the treatment by 1.7 and 2.2 times, and after CT (without DCV) – by 2.6 and 3.8 times. In group 3, TI was increased by 4 times, and CI by 2.5 times, being 81 % higher than in group 1. In primary patients, TI after 6 and 7 DCVs was similar to the normal values, and CI was increased during the treatment because of the accumulation of MWM254 due to disintegration of tumor masses in these patients, and then it was normalized after 7 DCVs. CI in patients of groups 2 and 3 decreased after each DCV session. 4 and more DCVs restored the functional activity of albumin and normalized the MWM content.Conclusion. Administration of DCV (at least 7–8 sessions) in CC patients receiving anticancer treatment or as monotherapy decreases endotoxicosis and restores detoxification capacity of albumin.
- Open Access
- 12 January 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (6) , 69-77-77
Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer
Введение. Белку Не-4 в последнее время уделяется большое внимание из-за его диагностической и прогностической ценности при эпителиальном раке яичников, что обусловлено его патогномонической ролью при этом заболевании. Еще одним значимым патогенетическим фактором является фактор роста эндотелия сосудов (VegF), который играет ключевую роль в неоангиогенезе. Цель исследования – изучение содержания Не-4 и VegF-a в опухолевой и неизмененной ткани яичника, сальнике и брюшине до и после неодъювантной химиотерапии с включением препаратов платины. Материал и методы. В исследование включены 93 больных раком яичников t2–3Nxm0–1 стадии, получивших хирургическое и химиотерапевтическое лечение в ФГБУ «НМИЦ онкологии» МЗ РФ, г. Ростова-на-Дону, из них у 42 больных лечение начато с неоадъювантной химиотерапии, за которой последовали операция и послеоперационная цитостатическая терапия; 51 пациентке лечение начинали с хирургического вмешательства, затем проводили химиотерапию. В тканях больных раком яичников определяли уровень Не-4 и VegF-a. В качестве контроля с целью определения референтных значений Не-4 и VegF-a в тканях явились образцы тканей 17 больных, прооперированных по поводу доброкачественной патологии. Результаты. Проведено сравнение между группами больных, получавших и не получавших неоадъювантную терапию, а также в группах больных в зависимости от эффективности цитостатического лечения. Оценку эффекта проводили через каждые 3 курса химиотерапии, используя шкалу Recist 1.1. Показано, что уровень Не-4 в первичных и метастатических тканях, пораженных и не пораженных опухолью, у больных раком яичников исходно повышен. При этом эффективность химиотерапевтического лечения напрямую связана с уровнем данного показателя, не изменяясь либо повышаясь при нечувствительных к лекарственному лечению опухолях. Уровень же VegF-a значимо отличался в тканях, пораженных и не пораженных опухолью, что свидетельствует о значимом его патогномоничном эффекте не «до», а на этапах морфологической малигнизации. Динамика снижения VegF-a в данном исследовании не зависела от эффекта химиотерапии. Заключение. Маркер Не-4 – патогномоничный фактор развития рака яичников, предшествующий морфологическим признакам злокачественности и отражающий эффективность химиотерапии, тогда как VegF-a является, скорее всего, следствием развития злокачественного процесса.
- 12 January 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (6) , 69-77-77
Open AccessInfluence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer
Введение. Белку Не-4 в последнее время уделяется большое внимание из-за его диагностической и прогностической ценности при эпителиальном раке яичников, что обусловлено его патогномонической ролью при этом заболевании. Еще одним значимым патогенетическим фактором является фактор роста эндотелия сосудов (VegF), который играет ключевую роль в неоангиогенезе. Цель исследования – изучение содержания Не-4 и VegF-a в опухолевой и неизмененной ткани яичника, сальнике и брюшине до и после неодъювантной химиотерапии с включением препаратов платины. Материал и методы. В исследование включены 93 больных раком яичников t2–3Nxm0–1 стадии, получивших хирургическое и химиотерапевтическое лечение в ФГБУ «НМИЦ онкологии» МЗ РФ, г. Ростова-на-Дону, из них у 42 больных лечение начато с неоадъювантной химиотерапии, за которой последовали операция и послеоперационная цитостатическая терапия; 51 пациентке лечение начинали с хирургического вмешательства, затем проводили химиотерапию. В тканях больных раком яичников определяли уровень Не-4 и VegF-a. В качестве контроля с целью определения референтных значений Не-4 и VegF-a в тканях явились образцы тканей 17 больных, прооперированных по поводу доброкачественной патологии. Результаты. Проведено сравнение между группами больных, получавших и не получавших неоадъювантную терапию, а также в группах больных в зависимости от эффективности цитостатического лечения. Оценку эффекта проводили через каждые 3 курса химиотерапии, используя шкалу Recist 1.1. Показано, что уровень Не-4 в первичных и метастатических тканях, пораженных и не пораженных опухолью, у больных раком яичников исходно повышен. При этом эффективность химиотерапевтического лечения напрямую связана с уровнем данного показателя, не изменяясь либо повышаясь при нечувствительных к лекарственному лечению опухолях. Уровень же VegF-a значимо отличался в тканях, пораженных и не пораженных опухолью, что свидетельствует о значимом его патогномоничном эффекте не «до», а на этапах морфологической малигнизации. Динамика снижения VegF-a в данном исследовании не зависела от эффекта химиотерапии. Заключение. Маркер Не-4 – патогномоничный фактор развития рака яичников, предшествующий морфологическим признакам злокачественности и отражающий эффективность химиотерапии, тогда как VegF-a является, скорее всего, следствием развития злокачественного процесса.
- Open Access
- 27 August 2020
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 1 (3) , 6-17
Development of postcastration syndrome and corrective effect of xenon in exponential dose regimen in young patients with gynecological cancers
Purpose of the study. Investigation of possible optimization of treatment in patients with breast cancer and cervical cancer with low-dose xenon therapy.Patients and methods. The study included 156 patients with pT1В2N0M0 cervical cancer (CC) and pT2N1M0 breast cancer (BC) of the reproductive age (29–45 years) after radical treatment, including forced surgical castration in hormone-positive breast cancer with concomitant gynecological pathology. Since the formation of pathological syndromes, 1 cycle (5 sessions) of low-dose xenon inhalation therapy (XT) was performed, with an algorithm for xenon dose calculation and exposure according to the exponential pattern of decreasing concentration and increasing exposure, with an individual approach. Together with general clinical and laboratory examinations, we used international scales for assessing the severity of the patient condition by the Kupperman menopausal index (MMI), ESAS, quality of life (MOS-SF-36), in a modification of the Russian International Center, pain (VAS); the types of general adaptive reactions were identified by the method of L.Kh. Garkavi.Results. Important advantages of a new method associated with a rapid regression of pathological psychosomatic symptoms were revealed after XT. MMI values (pp=0.02–0.04), and the coefficient of antistress reactions to stress increased, which was congruent with the data on improving the quality of life. Conclusion. High efficiency of the technology demonstrated possible prevention of surgical menopause development and clinical manifestations of postcastration syndrome in order to improve the quality of life and social rehabilitation of young patients with gynecological cancers.
- 27 August 2020
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 1 (3) , 6-17
Open AccessDevelopment of postcastration syndrome and corrective effect of xenon in exponential dose regimen in young patients with gynecological cancers
Purpose of the study. Investigation of possible optimization of treatment in patients with breast cancer and cervical cancer with low-dose xenon therapy.Patients and methods. The study included 156 patients with pT1В2N0M0 cervical cancer (CC) and pT2N1M0 breast cancer (BC) of the reproductive age (29–45 years) after radical treatment, including forced surgical castration in hormone-positive breast cancer with concomitant gynecological pathology. Since the formation of pathological syndromes, 1 cycle (5 sessions) of low-dose xenon inhalation therapy (XT) was performed, with an algorithm for xenon dose calculation and exposure according to the exponential pattern of decreasing concentration and increasing exposure, with an individual approach. Together with general clinical and laboratory examinations, we used international scales for assessing the severity of the patient condition by the Kupperman menopausal index (MMI), ESAS, quality of life (MOS-SF-36), in a modification of the Russian International Center, pain (VAS); the types of general adaptive reactions were identified by the method of L.Kh. Garkavi.Results. Important advantages of a new method associated with a rapid regression of pathological psychosomatic symptoms were revealed after XT. MMI values (pp=0.02–0.04), and the coefficient of antistress reactions to stress increased, which was congruent with the data on improving the quality of life. Conclusion. High efficiency of the technology demonstrated possible prevention of surgical menopause development and clinical manifestations of postcastration syndrome in order to improve the quality of life and social rehabilitation of young patients with gynecological cancers.